Literature DB >> 28104255

NMOSD triggered by yellow fever vaccination - An unusual clinical presentation with segmental painful erythema.

F Schöberl1, E Csanadi2, O Eren3, M Dieterich4, T Kümpfel5.   

Abstract

Neuromyelitis Optica Spectrum Disorder (NMOSD) is an immune-mediated disease of the central nervous system with the presence of aquaporin 4-antibodies (AQP4-abs) in most cases. We describe a patient who developed NMOSD after a yellow fever vaccination. He presented to us with an unusual painful erythema Th7-9 triggered by touch in the respective skin area due to a cervical spinal cord lesion affecting the dorsolateral parts of C6/7. To our knowledge, this is the first case of NMOSD with such a clinical presentation expanding the clinical spectrum of NMOSD. It is important to be aware of that a yellow fever vaccination can trigger NMOSD.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Devic's syndrome; NMOSD; Painful erythema; Transverse myelitis; Yellow fever vaccination

Mesh:

Substances:

Year:  2016        PMID: 28104255     DOI: 10.1016/j.msard.2016.11.009

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  3 in total

1.  Neuromyelitis optica associated with yellow fever vaccination.

Authors:  Bruno Bertoli Esmanhotto; Isabella Moraes Rocha; Carolina Rodrigues Laranjeira Vilar; Rafael Follador Haluch; Thaís Pimenta Valença
Journal:  Acta Neurol Belg       Date:  2020-06-10       Impact factor: 2.396

2.  Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report.

Authors:  Lisa Lohmann; Felix Glaser; Gabriel Möddel; Jan D Lünemann; Heinz Wiendl; Luisa Klotz
Journal:  BMC Neurol       Date:  2022-05-18       Impact factor: 2.903

3.  NMOSD typical brain lesions after COVID-19 mRNA vaccination.

Authors:  Julie Lévi-Strauss; Corentin Provost; Noémie Wane; Thomas Jacquemont; Nicolas Mélé
Journal:  J Neurol       Date:  2022-06-22       Impact factor: 6.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.